PAR
Get informed when a big investor buys or sells
+ FollowOvervalued by 391.7% based on the discounted cash flow analysis.
| Market cap | $636.84 Million |
|---|---|
| Enterprise Value | $1.03 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.09 |
| Beta | 1.32 |
| Outstanding Shares | 40,997,000 |
| P/E Ratio | -8.3 |
|---|---|
| PEG | 24.7 |
| Price to Sales | 1.29 |
| Price to Book Ratio | 0.71 |
| Enterprise Value to Revenue | 2.16 |
| Enterprise Value to EBIT | -13.9 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.45 |
| Debt to Equity | 0.56 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0660▲ 57.44% |
|---|---|
| Total Calls | 1,963,300▲ 92.07% |
| Total Puts | 2,092,900▲ 316.50% |
Holdings and activity of institutional investors.
| Ownership % | 121.31%▲ 2.74% |
|---|---|
| Total Invested | $655.19M▼ 62.33% |
| Investors Holding | 222▲ 3.00% |
No data
This powerful committee controls taxation, trade, and entitlement spending, including Medicare pricing. As an electromedical apparatus manufacturer, Par Technology's revenue and profitability would be directly affected by tax policy, trade tariffs, and Medicare reimbursement rates for its devices.
This committee directly regulates the FDA, which is the primary regulatory body for 'Electromedical and Electrotherapeutic Apparatus Manufacturing,' giving committee members direct insight into critical approval processes and industry standards.
This committee directly oversees the Department of Veterans Affairs and its funding, which significantly impacts government healthcare contractors and medical device manufacturers, a category that directly includes Par Technology.